{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:18:58Z","timestamp":1791497938690,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.msard.2023.105380","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T21:48:40Z","timestamp":1702417720000},"page":"105380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study"],"prefix":"10.1016","volume":"82","author":[{"given":"David","family":"Rog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace","family":"Brownlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Carod-Artal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lowndes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pendlebury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amerah","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-9169","authenticated-orcid":false,"given":"Erwin","family":"De Cock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.105380_bib0001","unstructured":"Aventis Pharma Limited, 2022. LEMTRADA 12 mg concentrate for solution for infusion, Summary of Product Characteristics. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/5409\/smpc#gref (Accessed July 2022)."},{"key":"10.1016\/j.msard.2023.105380_bib0002","unstructured":"Biogen Netherlands B.V, 2022. TYSABRI 300 mg concentrate for solution for infusion, Summary of Product Characteristics. Available at: https:\/\/www.medicines.org.uk\/emc\/medicine\/18447\/SPC\/TYSABRI+300+mg+concentrate+for+solution+for+infusion\/#gref (Accessed July 2022)."},{"issue":"9","key":"10.1016\/j.msard.2023.105380_bib0003","first-page":"2823","article-title":"An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries","volume":"25","author":"Body","year":"2017","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.msard.2023.105380_bib0004","series-title":"Unit Costs of Health and Social Care 2019","author":"Curtis","year":"2019"},{"key":"10.1016\/j.msard.2023.105380_bib0005","series-title":"Unit Costs of Health and Social Care 2020","author":"Curtis","year":"2020"},{"issue":"6","key":"10.1016\/j.msard.2023.105380_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157957","article-title":"Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: A time and motion study in eight countries","volume":"11","author":"De Cock","year":"2016","journal-title":"PLOS One"},{"issue":"3","key":"10.1016\/j.msard.2023.105380_bib0007","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cam4.573","article-title":"A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer","volume":"5","author":"De Cock","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.msard.2023.105380_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103458","article-title":"Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England","volume":"57","author":"Garjani","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2023.105380_bib0010","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2023.105380_bib0009","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","article-title":"Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm","volume":"31","author":"Giovannoni","year":"2018","journal-title":"Curr. Opin. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2023.105380_bib0011","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/13524585211033190","article-title":"Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis","volume":"27","author":"Hartung","year":"2021","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2023.105380_bib0012","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"key":"10.1016\/j.msard.2023.105380_bib0013","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jbi.2014.02.017","article-title":"Time motion studies in healthcare: what are we talking about?","volume":"49","author":"Lopetegui","year":"2014","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.msard.2023.105380_bib0015","unstructured":"Merck Serono Limited, 2022. MAVENCLAD 10 mg tablets, Summary of Product Characteristics. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/8435\/smpc#gref (Accessed July 2022)."},{"key":"10.1016\/j.msard.2023.105380_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103317","article-title":"COVID-19 in multiple sclerosis: clinically reported outcomes from the UK multiple sclerosis register","volume":"56","author":"Middleton","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105380_bib0026","unstructured":"MS Society, 2019. My MS My Needs 3 - 2019: Nation specific data tables. Available at: https:\/\/www.mssociety.org.uk\/sites\/default\/files\/2020-08\/MMMN3-nations-data-tables.pdf (Accessed July 2022)."},{"key":"10.1016\/j.msard.2023.105380_bib0017","unstructured":"MS Society, 2021. Neurology Now - 2021 Impact of COVID-19 on services \u2013 data tables. Available at: https:\/\/www.mssociety.org.uk\/sites\/default\/files\/2021-10\/Impact%20of%20COVID-19%20on%20Neurology%20Services%20-data%20tables%20%282021%29.pdf (Accessed July 2022)."},{"key":"10.1016\/j.msard.2023.105380_bib0018","unstructured":"MS Society, 2021. Neurology Now: The case for a new approach to neurology services. Available at: https:\/\/www.mssociety.org.uk\/sites\/default\/files\/2021-10\/Neuro%20Report%20V3.pdf (Accessed July 2022)."},{"key":"10.1016\/j.msard.2023.105380_bib0014","unstructured":"MS Trust, 2016. MS forward view: a consensus for the future of MS services. Available at: https:\/\/ukclinicalpharmacy.org\/wp-content\/uploads\/2017\/07\/MS-Trust-Forward-View-2016.pdf (Accessed July 2022)."},{"key":"10.1016\/j.msard.2023.105380_bib0027","unstructured":"MS Trust, 2021. Multiple sclerosis specialist nursing in the UK 2021: results from the MS trust nurse mapping survey. Available at: https:\/\/mstrust.org.uk\/health-professionals\/resources\/service-development\/ms-nurse-mapping (Accessed August 2022)."},{"key":"10.1016\/j.msard.2023.105380_bib0019","unstructured":"Novartis Pharmaceuticals UK Limited, 2022. Gilenya 0.25 mg hard capsules, Summary of Product Characteristics. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/4545#gref (Accessed July 2022)."},{"issue":"1","key":"10.1016\/j.msard.2023.105380_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7224\/1537-2073.2019-058","article-title":"Modeling the multiple sclerosis specialist nurse workforce by determination of optimum caseloads in the United Kingdom","volume":"23","author":"Punshon","year":"2021","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2023.105380_bib0021","unstructured":"Roche Products Limited, 2021. OCREVUS 300 mg Concentrate for Solution for Infusion. Summary of Product Characteristics. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/8898\/smpc#gref (Accessed July 2022)."},{"issue":"6","key":"10.1016\/j.msard.2023.105380_bib0022","first-page":"A135","article-title":"Raising the Bar for 4 MS UK Study Group. UK multiple sclerosis service audit of 70 centres: Observed staffing, proposed staffing, coping [Abstract]","author":"Rog","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2023.105380_bib0023","first-page":"A134","article-title":"Raising the bar for 4 MS UK study group. The UK multiple sclerosis service and DMT prescribing audit of 70 centres: overview","volume":"93","author":"Rog","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2023.105380_bib0024","first-page":"A134","article-title":"Raising the bar for 4 MS UK study group. UK multiple sclerosis service and DMT audit of 70 centres: variation in DMT prescribing","volume":"93","author":"Rog","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2023.105380_bib0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","article-title":"Association of British neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis","volume":"15","author":"Scolding","year":"2015","journal-title":"Pract. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2023.105380_bib0028","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1136\/jnnp-2021-328340","article-title":"Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study","volume":"93","author":"Williams","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823008805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823008805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:09:27Z","timestamp":1761901767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823008805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":28,"alternative-id":["S2211034823008805"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105380","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105380"}}